Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > Knight / Antibe ... for those who don't know ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5)
•••
Comment by Snowballgrowthon Jun 27, 2021 11:13am
85 Views
Post# 33457454

RE:RE:RE:Knight / Antibe ... for those who don't know ...

RE:RE:RE:Knight / Antibe ... for those who don't know ...
MrMugsy wrote: Snowball ... here's the illustrative partnering information - GUD has rights in the darker blue sections.  Lots of opportunities to still partner in other areas.

Just wondering if Exelon is a carrot and may be used to get access to LATAM for a more reasonable price (future).  Never know what Goodman is thinking but looking at the price paid and the desire to own Exelon IP is a little strange, all on its own.  Has to be more to it.

https://cdn-ceo-ca.s3.amazonaws.com/1gdh1q5-GUD%20rights%20in%20dark%20blue.PNG


Maybe some new sales to come after 2025-2026 but I don't see it as a catalyst for GUD. Too small potential vs GUD's market cap.  

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities